Epilepsy Portfolio And Late Stage Pipeline Are Expected To Drive Long Term Upside

Catalysts

About Praxis Precision Medicines

Praxis Precision Medicines develops targeted central nervous system therapies focused on genetically and mechanistically defined epilepsies and related disorders.

What are the underlying business or industry changes driving this perspective?

• Best in disease profile emerging for vormatrigine in refractory focal epilepsy, with rapid and deep seizure reduction on top of aggressive background regimens, positions the asset to capture share as treatment patterns evolve toward more effective agents. This supports the potential for higher peak revenue and durable pricing power.
• Planned expansion from adjunctive use to stand alone therapy via POWER3 directly addresses the large population cycling through multiple antiseizure medications. This creates a path from niche refractory use to earlier line positioning that can meaningfully expand the addressable market and long term revenue base.
• Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.
• Demonstrated recruitment strength in hard to enroll epilepsy populations and a cash runway extending into 2028 reduce execution and financing risk around five planned clinical readouts. This improves visibility on development timelines and limits near term dilution pressure on per share earnings power.
• Early signals of mood and quality of life benefits, if confirmed and reflected in labeling, could differentiate vormatrigine in a field crowded with tolerability challenged options. This could support superior persistence on therapy, higher net margins and enhanced lifecycle value for the franchise.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Praxis Precision Medicines's revenue will grow by 359.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from -3658.5% today to 12.4% in 3 years time.
• Analysts expect earnings to reach $89.5 million (and earnings per share of $4.11) by about January 2029, up from $-273.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $779.0 million in earnings, and the most bearish expecting $-217.4 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 188.3x on those 2029 earnings, up from -26.2x today. This future PE is greater than the current PE for the US Biotechs industry at 21.1x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.0%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Despite RADIANT's strong early data, pivotal POWER1, POWER2 and POWER3 trials must run through at least 2026. Any delay, underperformance or inconsistency versus the small initial cohort could undermine the best-in-disease positioning and materially reduce long-term revenue and earnings expectations.
• The current epilepsy treatment landscape already includes potent agents like cenobamate. If physicians remain entrenched in multi drug layering rather than rapidly adopting vormatrigine in earlier lines, Praxis may struggle to convert clinical differentiation into broad market share. This could pressure future revenue growth and limit operating leverage on net margins.
• Vormatrigine is being developed on top of aggressive background regimens with complex dose adjustment dynamics. If real world practice fails to mirror protocol-driven optimization seen in trials, higher-than-expected discontinuations or safety concerns could emerge over time and reduce persistence on therapy, negatively affecting both revenue and earnings quality.
• Praxis relies on a small number of late-stage CNS assets to justify long-term growth. Setbacks in any of the five planned readouts or in the relutrigine DEE program could weaken the perceived pipeline portfolio effect, increase the risk of future dilutive financing and lower per share earnings power even if headline revenue grows.
• Management is signaling an ambition to expand from refractory adjunct use into monotherapy and mood-related benefits. If regulators do not grant the desired label breadth or competing CNS innovations set a new standard of care before launch, pricing power and duration of peak sales could fall short of expectations, compressing net margins and long-term earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $449.13 for Praxis Precision Medicines based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $843.0, and the most bearish reporting a price target of just $83.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $724.1 million, earnings will come to $89.5 million, and it would be trading on a PE ratio of 188.3x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $286.4, the analyst price target of $449.13 is 36.2% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.